The North America Dipeptidyl Peptidase-4 Inhibitors Market is expanding steadily due to the growing burden of type 2 diabetes, increasing awareness of early disease diagnosis, and continuous innovation in diabetes therapeutics. Healthcare providers across the region are increasingly adopting individualized treatment strategies that incorporate dipeptidyl peptidase-4 inhibitors to improve...